Associate Professor Mark   Polizzotto
Adjunct Associate Professor

Associate Professor Mark Polizzotto


Medicine & Health
The Kirby Institute

Mark Polizzotto is Professor of Medicine at The Australian National University John Curtin School of Medical Research, where he leads the Clinical Hub in Interventional Research (CHOIR), and Senior Staff Haematologist at The Canberra Hospital.

Mark is a clinical triallist with a focus to developing new therapies to prevent and treat infection-related cancers. Mark's work on viral and HIV-associated cancers has influenced guidelines globally, including co-leading development of an oral immunomodulator for Kaposi sarcoma which led to the first new drug approval for KS in over 20 years.

From 2017 to 2021 he was head of the Therapeutic Research Program at the Kirby Institute. During that time he led several international randomised trials in HIV, influenza, and COVID-19 infection in collaboration with the U.S. National Institutes of Health, the World Health Organization, Unitaid, and others. He also led capacity development efforts in clinical trials for the NIH in West Africa and Indonesia.

His has published in key journals in the fields of infection, immunity, and malignancy including Blood, the Journal of Clinical Oncology, Lancet journals, Nature Medicine, and the New England Journal of Medicine

+61 2 9385 0900


  • Journal articles | 2021
    Associate Professor Mark Polizzotto
    Lundgren JD; Grund B; Barkauskas CE; Holland TL; Gottlieb RL; Sandkovsky U; Brown SM; Knowlton KU; Self WH; Files DC; Jain MK; Benfield T; Bowdish ME; Leshnower BG; Baker JV; Jensen JU; Gardner EM; Ginde AA; Harris ES; Johansen IS; Markowitz N; Matthay MA; Østergaard L; Chang CC; Davey VJ; Goodman A; Higgs ES; Murray DD; Murray TA; Paredes R; Parmar MKB; Phillips AN; Reilly C; Sharma S; Dewar RL; Teitelbaum M; Wentworth D; Cao H; Klekotka P; Babiker AG; Gelijns AC; Kan VL; Polizzotto MN; Thompson BT; Lane HC; Neaton JD, 2021, 'A neutralizing monoclonal antibody for hospitalized patients with Covid-19', New England Journal of Medicine, vol. 384, pp. 905 - 914,
    Journal articles | 2019
    Associate Professor Mark Polizzotto
    Davey RT; Fernández-Cruz E; Markowitz N; Pett S; Babiker AG; Wentworth D; Khurana S; Engen N; Gordin F; Jain MK; Kan V; Polizzotto MN; Riska P; Ruxrungtham K; Temesgen Z; Lundgren J; Beigel JH; Lane HC; Neaton JD; Butts J; Denning E; DuChene A; Krum E; Harrison M; Meger S; Peterson R; Quan K; Shaughnessy M; Thompson G; Vock D; Metcalf J; Dewar R; Rehman T; Natarajan V; McConnell R; Flowers E; Smith K; Hoover M; Coyle EM; Munroe D; Aagaard B; Pearson M; Cursley A; Webb H; Hudson F; Russell C; Sy A; Purvis C; Jackson B; Collaco-Moraes Y; Carey D; Robson R; Sánchez A; Finley E; Conwell D; Losso MH; Gambardella L; Abela C; Lopez P; Alonso H; Touloumi G; Gioukari V; Anagnostou O; Avihingsanon A; Pussadee K; Ubolyam S; Omotosho B; Solórzano C; Petersen T; Vysyaraju K; Rizza SA; Whitaker JA; Nahra R; Baxter J; Coburn P; Gardner EM; Scott JA; Faber L; Pastor E; Makohon L; MacArthur RA; Hillman LM; Farrough MJ; Polenakovik HM; Clark LA; Colon RJ; Kunisaki KM; DeConcini M; Johnson SA; Wolfe CR; Mkumba L; Carbonneau JY; Morris A; Fitzpatrick ME; Kessinger CJ; Salata RA; Arters KA; Tasi CM; Panos RJ; Lach LA, 2019, 'Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial', The Lancet Respiratory Medicine, vol. 7, pp. 951 - 963,